|
Link to this page
Your search term(s) "Benign Prostatic Hyperplasia" returned 18 results.
Page 1 2 Display All
Benign Prostatic Hyperplasia (BPH): Treatment Choices. Linthicum, MD: American Urologic Association Foundation (AUA). 2005. 13 p.
Benign prostatic hyperplasia (BPH) is a noncancerous (benign) growth of the cells within the prostate gland in men. Enlargement frequently causes a gradual squeezing of the urethra where it runs through the prostate; this can cause difficulty in urinating or other urinary problems. This booklet explains BPH and the various treatment options that can be used to manage any problems caused by BPH. Topics include the anatomy of the prostate, the symptoms of BPH, when BPH is usually treated, and treatment choices, including watchful waiting (no treatment), drug therapy, minimally-invasive treatments and surgical treatments. Drugs that are used include alpha-blockers, 5-alpha reductase inhibitors, combination therapies, and herbal therapies, including saw palmetto. Minimally-invasive therapies discussed include catheterization, Holmium laser enucleation of prostate (HoLEP), interstitial laser coagulation, prostatic stenting, transurethral microwave thermotherapy of the prostate (TUMT), and transurethral radio frequency needle ablation of the prostate (TUNA). Surgical techniques used for BPH include transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), and open prostatectomy. One chart summarizes the benefits and risks of each treatment option. The booklet includes a pre-test, glossary of terms, a chart of the American Urologic Association (AUA) BPH symptom score, and blank space for readers to record any questions or notes they may have. 1 figure. 2 tables.
Full Record Printer Friendly Version
Enlarged Prostate. Linthicum, MD: American Urologic Association Foundation (AUA). 2005. 7 p.
Benign prostatic hyperplasia (BPH) is a noncancerous (benign) growth of the cells within the prostate gland in men. Enlargement frequently causes a gradual squeezing of the urethra where it runs through the prostate; this can cause difficulty in urinating or other urinary problems. Written for men in their 50s and older, this booklet explains BPH and the various treatment options that can be used to manage any problems caused by BPH. Topics include the anatomy of the prostate, the importance of having a prostate check-up, the symptoms of BPH, diagnostic strategies used to confirm BPH (including the digital rectal exam, or DRE), when BPH is usually treated, and the possible impact of BPH on lifestyle. While most symptoms of BPH can be treated by a general practitioner, patients who have more bothersome symptoms, recurring urinary infections, bladders stones, or a complete inability to urinate should be seen by a urologist. The booklet includes a pre-test, glossary of terms, a chart of the American Urologic Association (AUA) BPH symptom score, and blank space for readers to record any questions or notes they may have. 2 figures. 1 table.
Full Record Printer Friendly Version
Is Benign Prostatic Hyperplasia a Risk Factor for Chronic Renal Failure?. Journal of Urology. 173 (3): 691-696. March 2005.
Benign prostatic hyperplasia (BPH) and chronic renal failure (CRF) are common medical conditions in older men. BPH can be a difficult syndrome to diagnose with certainty, often being described by conditions including lower urinary tract symptoms (including difficult urination), bladder outlet obstruction, and prostate enlargement. CRF (also called chronic kidney disease), can be diagnosed with glomerular filtration rate (GFR) tests. There is limited knowledge on the association between these two conditions, although chronic renal failure is a well described complication of obstructive BPH. This article reports on a review of the literature from 1966 to 2003 on the association between BPH and CRF. The authors note that most studies were referral based and did not represent the full spectrum of BPH in men. Differentiating acute and chronic renal failure, and acute and chronic urinary retention was often not done. Various combinations of chronic urinary retention with large residual urine volumes (greater than 300 ml), detrusor instability, and decreased bladder compliance were associated with CRF. Ureterovesicular junction obstruction from bladder remodeling in chronic urinary retention was the most commonly proposed mechanism for CRF. However, episodic acute urinary retention, urinary tract infections (UTI), and secondary hypertension (high blood pressure) may also have a role. Studies showed significant improvement in kidney function after prostate surgery, but the acuity of renal failure was generally not known. 59 references.
Full Record Printer Friendly Version
Prostate Health: Early Detection, Informed Choices. Mayo Clinic Health Letter. p. 1-8. June 2005.
This patient education article on prostate health is provided as a supplement to the Mayo Clinic Health Letter. The author provides an overview of prostate disease including the benefits of early detection, the physiology of the normal prostate, diagnostic tests that may be used, types of inflammation and benign prostatic enlargement, and treatment options. Specific topics covered include the symptoms of prostate problems, the prostate-specific antigen (PSA) test, bacterial prostatitis, chronic nonbacterial prostatitis, retrograde ejaculation, benign prostatic hyperplasia (BPH), drug therapy for BPH, laser therapy for BPH, transurethral resection of the prostate (TURP), prostate cancer, and postoperative problems (urinary incontinence or erectile dysfunction). One sidebar provides a chart comparing the different types of treatments available for early-stage prostate cancer. The article is illustrated with full-color line drawings of the problems and treatments discussed. 6 figures.
Full Record Printer Friendly Version
Urologic Diseases in America Project: Benign Prostatic Hyperplasia. Journal of Urology. 173 (4): 1256-1261. April 2005.
Benign prostatic hyperplasia (BPH), the most common benign neoplasm in American men, is a chronic condition that is associated with progressive lower urinary tract symptoms and affects nearly 75 percent of men by their 70s. In this review article, data from the Urologic Diseases in America BPH project are presented with an emphasis on health resource use trends between 1990 and 2000. Approximately 6.5 million of the 27 million white men who are 50 to 79 years old in the United States in 2000 were estimated to meet the criteria for discussing treatment. Lower urinary tract symptoms (LUTS) associated with BPH include nocturia (getting up to urinate at night), incomplete emptying of the bladder, urinary hesitancy (difficulty beginning or ending the urinary stream), weak stream, frequency, and urgency. In 2000, approximately 4.5 million visits were made to physician offices for a primary diagnosis of BPH and almost 8 million visits were made with a primary or secondary diagnosis of BPH. In the same year, approximately 87,400 prostatectomies (removal of the prostate) for BPH were performed in inpatients in nonfederal hospitals in the U.S. While the number of outpatient visits for BPH increased consistently during the 1990s, there was a dramatic decrease in the use of transurethral prostatectomy (TURP), inpatient hospitalization, and length of hospital stay for this condition. These trends reflect the changing medical management for BPH, which is emphasizing the use of pharmacological agents and minimally invasive therapies. In 2000, the direct costs of BPH treatment were estimated to be $1.1 billion, exclusive of outpatient drug therapy. The authors conclude that, given the impact that BPH has on quality of life and health care costs, additional research into the risk factors, diagnostic and therapeutic resource use, and effectiveness and cost benefit of therapies is necessary. 10 tables. 21 references.
Full Record Printer Friendly Version
Effects of Transurethral Resection of Prostate on the Quality of Life of Patients with Benign Prostate Hyperplasia. Journal of the American College of Surgeons. 198(3): 394-403. March 2004.
This article reports on a prospective study that investigated the effects of transurethral resection of the prostate (TURP) on quality of life (QOL) and urinary symptoms in patients with benign prostatic hyperplasia (BPH). The study included 30 patients without significant comorbidities who were undergoing TURP. The QOL of patients who underwent TURP for BPH had significantly improved at 3 months after their operation. The magnitude and timing of this improvement may serve as a useful comparator in determining the optimal treatment of patients with BPH. 5 figures. 24 references.
Full Record Printer Friendly Version
Enlarged Prostate. Mayo Clinic Health Letter. 22(1): 4-5. January 2004.
This newsletter article provides information for men with enlarged prostate (benign prostatic hyperplasia, BPH) whose condition has not responded to the typical medications used. The author reviews other minimally invasive therapies and surgery. Generally, surgery is considered the most effective way to relieve BPH symptoms, but advances in laser treatment have meant faster recoveries and minimal side effects. The article describes transurethral resection of the prostate (TURP), laser therapies, and photoselective vaporization of the prostate (PVP). 2 figures.
Full Record Printer Friendly Version
Quick Reference for Urologists. Linthicum, MD: American Urological Association. 2004. 37 p.
This pocket-sized booklet summarizes the American Urological Association's (AUA) most recently published guidelines on premature ejaculation, benign prostatic hyperplasia (BPH), priapism, antibiotic prophylaxis, male infertility, prostate-specific antigen (PSA), microscopic hematuria, and bladder cancer. AUA guidelines provide the practitioner with clear principles and strategies for quality patient care and do not establish a fixed set of rules that preempt physician judgment. In each section, the booklet includes a definition, overview of patient evaluation, symptoms, diagnosis and diagnostic tests, patient management, medical treatment, and surgical techniques (where appropriate). Emerging technologies are described. A bulk of the material is presented in tabular format; most sections include a patient care algorithm. The introductory material notes that the booklet contains information about certain drug uses that are not approved by the Food and Drug Administration (FDA); readers are encouraged to read prescribing information about indications, contraindications, precautions, and warnings. 7 figures. 10 tables.
Full Record Printer Friendly Version
Page 1 2 Display All
Start a new search.
|
